Pipeline | Explore Innovative Treatments - Act Now
Revium Rx develops lipid-based therapies for antimicrobial resistance, cancer, and vaccines.

ReviumRx is a preclinical biotechnology company developing lipid-based drug delivery therapies.
reviumrx.comCrawled Nov 9, 2026
Revium Rx develops lipid-based therapies for antimicrobial resistance, cancer, and vaccines.
Revium Rx uses liposomal technology to deliver targeted drug treatments, improving efficacy and reducing side effects.
Completes Acquisition of LipoVation Ltd.
significant progress in its regulatory and manufacturing programs
Bloom Coaching offers personalized business coaching and growth strategies for entrepreneurs.
Revium Rx is a biotech company developing lipid-based therapies for resistant infections.
10 Hamenofim st. Herzliya, Israel 4672561 Phone: +1-800-5191687 Email: info@reviumrx.com
Revium RX develops next-generation lipid-based therapies addressing antimicrobial resistance and oncology challenges, focusing on targeted drug delivery and unmet medical needs.
Revium RX develops next-generation lipid-based therapies addressing antimicrobial resistance and oncology challenges, focusing on targeted drug delivery and unmet medical needs.
Revium Rx outlines its privacy practices, data collection methods, and user rights in its privacy policy.
Revium Rx submits a clinical trial application to the Israeli Ministry of Health for its Nano-Mupirocin formulation, aiming for first-in-human Phase 1 trials in early 2026. The drug targets antibiotic-resistant bacterial infections, leveraging a nanotechnology-enhanced version of the antibiotic mupirocin. This development marks a step toward addressing growing concerns over multi-drug-resistant pathogens.
Revium Rx progresses its **nano-mupirocin** formulation into **Phase 1 clinical trials** to address antibiotic-resistant bacterial infections. The company develops nanotechnology-based antimicrobials targeting multidrug-resistant pathogens. This milestone follows preclinical validation of the drug’s safety and efficacy profiles.
Revium Rx develops nanoparticle-based treatments to combat antibiotic-resistant infections. The company targets life-threatening infections by offering alternative therapies beyond conventional antibiotics. Inna Martin, COO and President, highlights the urgency of new solutions to prevent minor infections from becoming deadly.
Revium Rx acquires LipoVation Ltd to expand its focus on nanoparticle-based drug development. The move integrates LipoVation’s technology into Revium Rx’s portfolio, aiming to accelerate advancements in drug delivery systems. Both companies specialize in innovative pharmaceutical solutions.
Revium Rx is progressing toward Phase 1 clinical trials for **Nano-Mupirocin**, a lipid-based systemic formulation of the antibiotic mupirocin. The company’s regulatory and manufacturing preparations support testing of this novel treatment for antibiotic-resistant infections. Nano-Mupirocin aims to address growing resistance challenges by delivering an existing potent antibiotic in a new systemic form.